Abstract
Psychiatric drug discovery needs to close the systems neuroscience gap to improve the clinical success rates of candidate drugs with novel mechanisms of action.
References
Potter, D. et al. Review of clinical correlates of P50 sensory gating abnormalities in patients with schizophrenia. Schizophr. Bull. 32, 692–700 (2006).
Leiser, S. C. et al. A cog in cognition: how the α7 nicotinic acetylcholine receptor is geared towards improving cognitive deficits. Pharmacol. Ther. 122, 302–311 (2009).
Akil, H. et al. Medicine. The future of psychiatric research: genomes and neural circuits. Science 327, 1580–1581 (2010).
Tye, K. M. & Deisseroth, K. Optogenetic investigation of neural circuits underlying brain disease in animal models. Nature Rev. Neurosci. 13, 251–266 (2012).
Cuthbert, N. & Insel, T. R. Toward new approaches to psychotic disorders: the NIMH Research Domain Criteria Project. Schizophr. Bull. 36, 1061–1062 (2010).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary information Figure S1
Conventional and psychobiological target definitions. (PDF 263 kb)
Rights and permissions
About this article
Cite this article
Sarter, M., Tricklebank, M. Revitalizing psychiatric drug discovery. Nat Rev Drug Discov 11, 423–424 (2012). https://doi.org/10.1038/nrd3755
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3755
- Springer Nature Limited
This article is cited by
-
Time to re-engage psychiatric drug discovery by strengthening confidence in preclinical psychopharmacology
Psychopharmacology (2021)
-
Rescuing the attentional performance of rats with cholinergic losses by the M1 positive allosteric modulator TAK-071
Psychopharmacology (2020)
-
Opportunities and challenges in modeling human brain disorders in transgenic primates
Nature Neuroscience (2016)